Cytokine-based therapies in inflammatory bowel disease

Current Opinion in Gastroenterology

Volumn 15, Issue 4, 1999, Pages 302-307

  Kam, Lori Y ^a,b   Targan, Stephan R ^a  

^a UNIVERSITY OF CALIFORNIA   (United States)

^b CEDARS SINAI MEDICAL CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ACETYLSALICYLIC ACID; AMRINONE; ANTIINFLAMMATORY AGENT; BUDESONIDE; CD3 ANTIGEN; CD4 ANTIGEN; CYTOKINE; GAMMA INTERFERON; GLUCOCORTICOID; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; INTERLEUKIN 1; INTERLEUKIN 10; INTERLEUKIN 11; INTERLEUKIN 12; INTERLEUKIN 18; INTERLEUKIN 6; LISOFYLLINE; PHOSPHODIESTERASE IV INHIBITOR; ROLIPRAM; SALAZOSULFAPYRIDINE; STAT3 PROTEIN; STAT4 PROTEIN; THALIDOMIDE; THALIDOMIDE DERIVATIVE; TUMOR NECROSIS FACTOR ALPHA; TUMOR NECROSIS FACTOR ALPHA ANTIBODY;

ARTICLE; CHRONIC INFLAMMATION; CROHN DISEASE; CYTOKINE PRODUCTION; ENTERITIS; HUMAN; MOUSE; NONHUMAN; RAT; REGULATORY MECHANISM; T LYMPHOCYTE ACTIVATION;

EID: 0032771184     PISSN: 02671379     EISSN: None     Source Type: Journal    
DOI: 10.1097/00001574-199907000-00005     Document Type: Article

References (41)

1. 1 Bregenholt S, Delbro C, Claesson MH: T-cell transfer and cytokine/TCR gene deletion models in the study of inflammatory bowel disease. APMIS 1997, 105:655-662.
2. 2 Watanabe M, Hosoda Y, Okamoto S, Yamazaki M, Inoue N, Ueno Y, et at: CD45RChighCD4+ intestinal mucosal lymphocytes infiltrating in the inflamed colonie mucosa of a novel rat colitis model induced by TNB immunization. Clin Immunol Immunopathol 1998, 88:46-55.
3. 3 Stronkhorst A, Radema S, Yong SL, Bijl H, ten Berge IJ, Tytgat GN, van Deventer SJ: CD4 antibody treatment in patients with active Crohn's disease: a phase 1 dose finding study. Gut 1997, 40:320-327.
4. 4 Canva-Delcambre V, Jacquot S, Robinet E, Lemann M, Drouet C, Labalette M, et al: Treatment of severe Crohn's disease with anti-CD4 monoclonal antibody. Aliment Pharmacol Ther 1996, 10:721-727.
5. 5 Wittig B, Schwarzler C, Fohr N, Gunthert U, Zoller M: Curative treatment of an experimentally induced colitis by a CD44 variant V7-specific antibody. J Immunol 1998, 161:1069-1073. A therapeutic approach using a new cell surface receptor antibody is described.
6. 6 Neurath MF, Becker C, Barbulescu K: Role of NFκB in immune and inflammatory responses in the gut. Gut 1998, 43:856-860. This is a comprehensive review of NFκB regulation and activity.
7. 7 Neurath MF, Pettersson S, Buschenfelde KHMZ, Strober W: Local administration of antisense phosphorothioate oligonucleotides to the p65 subunit of NFκB abrogates established experimental colitis in mice. Nat Med 1996, 2:998-1004.
8. 8 Khaled A, Butfiloske EJ, Sobel E, Schiffenbauer J: Use of phosphorothioate-modified oligodeoxynucleotides to inhibit NF-κB expression and lymphocyte function. Clin Immunol Immunopathol 1998, 86:170-179. Use of antisense technology to inhibit NFκB activity and production is described.
9. 9 Haas M, Page S, Page M, Neumann FJ, Marx N, Adam M, et al: Effect of proteasome inhibitors on monocytic IκB-α and -β depletion, NF-κB activation, and cytokine production. J Leukoc Biol 1998, 63:395-404. This article reports a novel approach to NFκB inhibition.
10. 10 Schreiber S, Nikolaus S, Hampe J: Activation of nuclear factor κB in inflammatory bowel disease. Gut 1998, 42:477-484. This is a comprehensive review of NFκB regulation and activity.
11. 11 Mazzeo D, Panina-Bordignon P, Recalde H, Sinigaglia F, D'Ambrosio D: Decreased IL-12 production and Th1 cell development by acetylsalicylic acid-mediated inhibition of NF-κB. Eur J Immunol 1998, 28:3205-3213.
12. 12 Yin MJ, Yamamoto Y, Gaynor RB: The anti-inflammatory agents aspirin and salicylate inhibit the activity of IκB kinase-B. Nature 1998, 396:77-80. This article describes the mechanism of NFκB inhibition and subsequent decreased IL-12 production by these anti-inflammatory agents.
13. 13 Wahl C, Liptay S, Adler G, Schmid RM: Sulfasalazine: a potent and specific inhibitor of nuclear factor kappa B. J Clin Invest 1998, 101:1163-1174. A new mechanism of action for sulfasalazine via inhibition of IκB phosphorylation is described.
14. 14 Wirtz S, Finotto S, Kanzler S, Lohse AW, Blessing M, Lehr HA, et al: Cutting edge: chronic intestinal inflammation in STAT-4 transgenic mice: characterization of disease and adoptive transfer by TNF-plus IFN-γ producing CD4+ T cells that respond to bacterial antigens. J Immunol 1999, 162:1884-1888. A transgenic mouse model demonstrates the development of chronic intestinal inflammation in mice with overexpression of STAT-4. This study supports the role of IL-12/STAT-4 regulation in the development of chronic inflammation and the Th1 response.
15. 15 Takeda K, Clausen GI, Kaisho T, Tsujimura T, Terada N, Forster I, Akira S: Enhanced TH-1 activity and development of chronic enterocolitis in mice devoid of STAT-3 in macrophages and neutrophils. Immunity 1999, 10:39-49. Deficiency of STAT-3 leads to severe suppression of IL-10-mediated responses and subsequent increase in production of Th1 cytokines (TNF-α, IL-1, IFN-γ, IL-6).
16. 16 Targan S, Hanauer S, van Deventer SJH, Mayer L, Present DH, Braakman T, et al, Crohn's Disease cA2 Study Group: A short term study of chimeric monoclonal antibody cA2 to tumor necrosis factor α for Crohn's disease. N Engl J Med 1997, 337:1029-1035.
17. 17 Marriott JB, Westby M, Cookson S, Guckian M, Goodbourn S, Muller G, et al: CC-3052: a water-soluble analog of thalidomide and potent inhibitor of activation-induced TNF-alpha production. J Immunol 1998, 161:4236-4243. A novel PDE IV inhibitor with potent anti-TNF properties is described.
18. 18 Eigler A, Siegmund B, Emmerich U, Baumann KH, Hartmann G, Endres S: Anti-inflammatory activities of cAMP-elevating agents: enhancement of IL-10 synthesis and concurrent suppression of TNF production. J Leukoc Biol 1998, 63:101-107.
19. 19 Gomis-Ruth FX, Meyer EF, Kress LF, Politi V: Structures of adamalysin II with peptidic inhibitors: implications for the design of tumor necrosis factor α convertase inhibitors. Protein Sci 1998, 7:283-292.
20. 20 Weinblatt ME, Kremer JM, Bankhurst AD, Bulpitt KJ, Bleischmann RM, Fox RI, et al: A trial of etanercept, a recombinant tumor necrosis factor receptor:Fc fusion protein, in patients with rheumatoid arthritis receiving methotrexate. N Engl J Med 1999, 340:253-259.
21. 21 Strober W, Ludviksson BR, Fuss IJ: The pathogenesis of mucosal inflammation in murine models of inflammatory bowel disease and Crohn's disease. Ann Intern Med 1998, 128:848-856. This article presents a comprehensive review of genetic and experimental animal models of IBD.
22. 22 Monteleone G, Biancone L, Marasco R, Morrone G, Marasco O, Luzza F, Pallone F: Interleukin 12 is expressed and actively released by Crohn's disease intestinal lamina propria mononuclear cells. Gastroenterology 1997, 112:1169-1178.
23. 23 Visser J, van Boxel-Dezaire A, Methorst D, Brunt T, de Kloet ER, Nagelkerken L: Differential regulation of interleukin-10 (IL-10) and IL-12 by glucocorticoids in vitro. Blood 1998, 91:4255-4264.
24. 24 Larsson S, Linden M: Effects of a corticosteroid, budesonide, on production of bioactive IL-12 by human monocytes. Cytokine 1998, 10:786-789.
25. 25 Hasko G, Szabo C, Nemeth ZH, Salzman AL, Vizi ES: Suppression of IL-12 production by phosphodiesterase inhibition in murine endotoxemia is IL-10 independent. Eur J Immunol 1998, 28:468-472. Additional anticytokine effects of PDE IV inhibitors are described.
26. 26 Bright JJ, Du C, Coon M, Sriram S, Klaus S: Prevention of experimental allergic encephalomyelitis via inhibition of IL-12 signaling and IL-12-mediated Th1 differentiation: an effect of the novel anti-inflammatory drug lisofylline. J Immunol 1998, 161:7015-7022.
27. 27 Becher B, Blain M, Giancomini PS, Antel JP: Inhibition of Th1 polarization by soluble TNF receptor is dependent on antigen presenting cell-derived IL-12. J Immunol 1999, 162:684-688. TNFR:Fc fusion protein is used to inhibit IFN-γ and IL-12 production.
28. 28 Yoshimoto T, Wang CR, Yoneto T, Waki S, Sunaga S, Komagata Y, et al: Reduced T helper 1 responses in IL-12 p40 transgenic mice. J Immunol 1998, 160:588-594. This study introduces the provocative concept that the bioactivity of IL-12 may be antagonized by its p40 subunit.
29. 29 Christ AD, Stevens AC, Koeppen H, Walsh S, Omata F, Devergne O, et al: An interleukin 12-related cytokine is up-regulated in ulcerative colitis but not in Crohn's disease. Gastroenterology 1998, 115:307-313. A novel glycoprotein (EB13) that is homologous to IL-12p40 and found in ulcerative colitis versus Crohn's disease is described. This study indicates an up-regulation of the Th2 response through IL-12 inhibition by a protein homologous to the p40 subunit.
30. 30 Dinarello CA: Interleukin-1 beta, interleukin-18, and the interleukin-1 beta converting enzyme. Ann M Y Acad Sci 1998, 856:1-11. A comprehensive update and review of IL-18, IL-1, and IL-1β-converting enzyme regulation is presented.
31. 31 McAlindon ME, Hawkey CJ, Mahida YR: Expression of interleukin 1B and interleukin 1B converting enzyme by intestinal macrophages in health and inflammatory bowel disease. Gut 1998, 42:214-219.
32. 32 Xu D, Chan WL, Leung BP, Hunter D, Schultz K, Carter RW, et al: Selective expression and functions of interleukin 18 on T helper (Th) type 1 but not Th2 cells. J Exp Med 1998, 188:1485-1492. This article describes the effect of IL-12 and IL-18R interactions on the regulation of inflammation.
33. 33 Nishida Y, Torigoe K, Aizawa Y, Okura T, Mori T, Yamauchi H, et al: Cloning and expression of a single-chain Fv fragment specific for the human interleukin 18 receptor. Hybridoma 1998, 17:577-580. A new murine-human IL-18R antibody that inhibits IFN-γ production is described.
34. 34 Herfarth HH, Bocker U, Janardhanam R, Sartor RB: Subtherapeutic corticosteroids potentiate the ability of interleukin 10 to prevent chronic inflammation in rats. Gastroenterology 1998, 115:856-865.
35. 35 Van Deventer SJH, Elson CO, Fedorak RN, Crohn's Study Group: Multiple doses of intravenous interleukin 10 in steroid refractory Crohn's disease. Gastroenterology 1997, 113:383-389.
36. 36 Lugering N, Kucharzik T, Stein H, Winde G, Lugering A, Hasilik A, et al: IL-10 synergizes with IL-4 and IL-13 in inhibiting lysosomal enzyme secretion by human monocytes and lamina propria mononuclear cells from patients with inflammatory bowel disease. Dig Dis Sci 1998, 43:706-714. A new therapeutic approach using combination cytokine therapy is described.
37. 37 Kucharzik T, Lugering N, Adolf M, Domschke W, Stoll R: Synergistic effect of immunoregulatory cytokines on peripheral blood monocytes from patients with inflammatory bowel disease. Dig Dis Sci 1997, 42:805-812.
38. 38 Sutterwala F, Noel G, Salgame P, Mosser DM: Reversal of proinflammatory responses by ligating the macrophage Fc(gamma) receptor type I. J Exp Med 1998, 188:217-222. A novel anticytokine approach using up-regulation of IL-10 through macrophage receptor ligation is presented.
39. 39 Peterson RL, Wang L, Albert L, Keith JC, Dorner AJ: Molecular effects of recombinant human interleukin 11 in the HLA-B27 rat model of inflammatory bowel disease. Lab Invest 1998, 78:1503-1512. Human recombinant IL-11 therapy attenuates experimental intestinal inflammation.
40. 40 Hogaboam CM, Vallance BA, Humar A, Addison CL, Graham FL, Gauldie J, Collins SM: Therapeutic effects of interleukin-4 gene transfer in expertmental inflammatory bowel disease. J Clin Invest 1997, 100:2766-2776.
41. 41 Jobin C, Panja A, Hellerbrand C, Iimuro Y, Didonato J, Brenner DA, Sartor RB: Inhibiton of proinflammatory molecule production by adenovirus-mediated expression of a nuclear factor κB super-repressor in human intestinal epithelial cells. J Immunol 1998, 160:410-418. A novel approach to NFκB inhibition uses genetically engineered adenovirus to deliver mutant IκB locally into intestinal epithelial cells.